<DOC>
	<DOCNO>NCT01243060</DOCNO>
	<brief_summary>In recent year , increase focus cognitive side effect sleep-inducing medication may contribute unusual behavior unexpected awakening night . Concerns regard side effect lead class Food Drug Administration ( FDA ) warn sleep-inducing medication . Almorexant experimental sleep-inducing medication new class medication extensively develop multiple pharmaceutical company . Medications class block wake/arousal center brain function protein call hypocretins . The goal study evaluate impact cognitive performance almorexant vs. zolpidem ( approve sleep aid ) placebo .</brief_summary>
	<brief_title>Effect Hypocretin/Orexin Antagonist Neurocognitive Performance</brief_title>
	<detailed_description>Up 216 healthy volunteer enrol participate 10 day study . After screen procedure complete ( SFVAMC ) , Days 1 - 7 take place subject ' home , sleep/wake activity monitor . Days 8 - 10 take place Moffitt Hospital . On Day 10 , subject take one dose either almorexant 100mg , almorexant 200mg , zolpidem 10mg , placebo . Cognitive test administer subject throughout Day 10 . Subjects return follow-up safety lab within 5 - 12 day dose study medication . Based animal study , anticipated subject take almorexant less cognitively impaired take zolpidem .</detailed_description>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>To participate study , participant must : Be age 19 39 Be good physical health Be good sleeper consistent bedtime wake time Not problem fall stay asleep Be nonsmoker Meet study criterion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Sleep Aid</keyword>
</DOC>